EMBC
Embecta Corp.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$5.80
+1.93%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.0B | 1.1B | 1.1B | 1.1B | 1.1B |
| Cost of Revenue | 408.6M | 400.9M | 394.2M | 370.9M | 354.6M |
| Gross Profit | 610.1M | 679.5M | 728.9M | 749.9M | 774.9M |
| Operating Expenses | |||||
| R&D Expense | 20.2M | 21.5M | 78.8M | 85.2M | 65.0M |
| SG&A Expense | 240.7M | 331.4M | 365.1M | 341.3M | 294.8M |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 96.1M | (2.7M) | 110.8M | 93.8M | 37.0M |
| Total Operating Expenses | 357.0M | 350.2M | 554.7M | 520.3M | 396.8M |
| Cost and Expenses | 765.6M | 751.1M | 948.9M | 891.2M | 751.4M |
| Operating Income (EBIT) | 253.1M | 329.3M | 174.2M | 229.6M | 378.1M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | 96.7M | 107.3M | 112.3M | 107.0M | 46.2M |
| Net Interest Income | (96.7M) | (107.3M) | (112.3M) | (107.0M) | (46.2M) |
| Other Non-Op Income/Expense | (128.1M) | (193.0M) | (130.0M) | (123.9M) | (121.5M) |
| Non-Operating Income (excl Interest) | 31.4M | 85.7M | 17.7M | 16.9M | 75.3M |
| EBT (Pre-Tax Income) | 125.0M | 136.3M | 44.2M | 105.7M | 256.6M |
| Income Tax Expense | 37.5M | 40.9M | (34.1M) | 35.3M | 33.0M |
| Bottom Line | |||||
| Net Income | 87.5M | 95.4M | 78.3M | 70.4M | 223.6M |
| Earnings from Cont. Ops | 87.5M | 95.4M | 78.3M | 70.4M | 223.6M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 87.5M | 95.4M | 78.3M | 70.4M | 223.6M |
| Per Share | |||||
| Basic EPS | $1.49 | $1.64 | $1.34 | $1.23 | $3.92 |
| Diluted EPS | $1.48 | $1.62 | $1.34 | $1.22 | $3.89 |
| Revenue Per Share | $17.42 | $18.53 | $19.26 | $19.58 | $19.80 |
| Shares | |||||
| Basic Shares Outstanding | 58.5M | 58.3M | 58.3M | 57.2M | 57.1M |
| Diluted Shares Outstanding | 58.5M | 58.9M | 58.3M | 57.8M | 57.1M |
| Profitability Metrics | |||||
| EBITDA | 273.7M | 294.7M | 199.0M | 245.4M | 334.5M |
| D&A | 52.0M | 51.1M | 42.5M | 32.7M | 31.7M |
| EBIT | 221.7M | 243.6M | 156.5M | 212.7M | 302.8M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026